For many years, platinum plus etoposide regimens had been recommended for patients with extensive stage small cell lung cancer (SCLC); however, the preferred regimens for extensive stage SCLC now include immune checkpoint inhibitors, either atezolizumab or durvalumab, plus platinum plus etoposide.